# A Study to Evaluate the Safety and Efficacy of RQC for AMD

> **NCT05062486** · PHASE2 · COMPLETED · sponsor: **Paul A Knepper, MD PhD** · enrollment: 55 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** Resveratrol, Quercetin, Curcumin (RQC)
- **DRUG:** Curcumin

## Key facts

- **NCT ID:** NCT05062486
- **Lead sponsor:** Paul A Knepper, MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-04
- **Primary completion:** 2024-11-07
- **Final completion:** 2024-11-07
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05062486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05062486, "A Study to Evaluate the Safety and Efficacy of RQC for AMD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05062486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*